Evotec SE (MIL:1EVT) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1EVT Evotec SE MIL:1EVT
38 GF Score
Price €3.71
GF Value €7.53
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

MIL:1EVT
38GF Score
Evotec SE MIL:1EVT
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Evotec SE (MIL:1EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of €3.71 is trading 50.8% below its estimated GF Value™ of €7.53. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for MIL:1EVT:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €7.53 vs. price of €3.71 (50.8% below fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the MIL:1EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
38GF Score

Get the complete analysis for MIL:1EVT

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.71
Price
€7.53
GF Value